Gilead Sciences, Inc. (NASDAQ:GILD) Stake Reduced by Clarius Group LLC

Clarius Group LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,301 shares of the biopharmaceutical company’s stock after selling 221 shares during the quarter. Clarius Group LLC’s holdings in Gilead Sciences were worth $501,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Financial Counselors Inc. boosted its holdings in shares of Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 128 shares during the period. Steph & Co. increased its holdings in shares of Gilead Sciences by 1.9% in the 4th quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock valued at $611,000 after purchasing an additional 142 shares during the period. First Affirmative Financial Network boosted its holdings in shares of Gilead Sciences by 3.5% during the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 147 shares during the period. Rathbones Group PLC grew its position in Gilead Sciences by 3.7% during the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 150 shares in the last quarter. Finally, MCF Advisors LLC increased its stake in Gilead Sciences by 2.1% in the 1st quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 152 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a report on Friday, April 19th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research note on Wednesday, April 24th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Maxim Group dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $82.00.

Gilead Sciences Price Performance

NASDAQ GILD traded down $1.59 on Friday, hitting $74.00. 1,691,663 shares of the company were exchanged, compared to its average volume of 7,345,524. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market cap of $92.19 billion, a P/E ratio of 206.97, a P/E/G ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The firm has a 50 day moving average of $69.62 and a two-hundred day moving average of $70.55.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. On average, equities analysts predict that Gilead Sciences, Inc. will post 3.73 EPS for the current year.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.